Expanded Access Study for Renal Transplant Patients With Envarsus XR ™

• Status: Approved for marketing
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR (Tacrolimus).

Details

• Lead Sponsor: Veloxis Pharmaceuticals
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Eligible patients will fulfill all of the following criteria:

1. Patient age ≥18years old

2. Willing to give written informed consent and is able to speak, write and understand English

3. Patient understands potential risks or benefits with treatment of Envarsus XR

4. Patients who have received a primary or secondary kidney transplant

5. Patient who have received prior treatment with Envarsus XR (LCP-Tacro) and who are not currently participating in an Envarsus/LCP-Tacro study OR

6. The treating Investigator has identified the patient as having a medical necessity for switching from their current tacrolimus treatment to Envarsus XR: Investigator is aware the medical necessity for switching is not related to the inability to purchase available tacrolimus.

Exclusion Criteria:

• Patients fulfilling any of the following criteria are NOT eligible for study inclusion:

1. Recipients of organ transplants other than kidney

2. Pregnant or nursing (lactating) women, or planning to become pregnant, where pregnancy is defined as a state of female after conception and until the termination of gestation, confirmed by a positive hCG serum or urine laboratory test.

3. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant who are unwilling to use a defined SOC method of contraception, UNLESS they are

• Women whose career, lifestyle, or sexual orientation preclude intercourse with a male partner

• Women whose partners have been sterilized by vasectomy or other medically approved means